mounjaro tirzepatide news https://t.co/QYMeNhMdZk Lilly's (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease Eli Lilly launches weight-loss drug

The Midpoint Cohort is designed to be identical to the ongoing Pivotal Cohort, serving as an early readout to reinforce confidence in the pivotal program and provide initial validation of the study design and endpoints

Here are the differences in your body that you may start to notice within a few weeks of starting a GLP-1 weight-loss medication like Wegovy and what the journey is really likely to look like

During the study, hydration levels increased up to 200% compared to placebo, and even 7 days after stopping the treatment hydration status was largely preserved

Lower Overhead Structure Telehealth platforms operate with lower overhead than traditional pharmaceutical companies: no physical clinic locations to maintain, providers work remotely reducing facility costs, streamlined administrative processes through technology, and efficient inventory management

It has also proved to be effective for those with chronic bronchitis, emphysema, chronic respiratory allergies or any kind of scarring of the lung from previous injury